The Pharma Summit 2012
Can Biopharma Go from 'Value Destruction' to Double Returns?
By Nuala Moran
Wednesday, February 15, 2012
LONDON Pricing pressures, piled on top of R&D productivity problems, have cut the return on investment and left many asking if developing new drugs is worth the risk.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.